Public Health Initiatives

To Meaningfully Address the Opioid Crisis, Purdue is Pursuing Three Public Health Initiatives

The Initiatives seek to increase access to treatments for opioid use disorder and opioid overdose by developing and providing, at no profit, millions of doses of the following medicines:

1. Opioid Use Disorder Treatment – Buprenorphine/Naloxone Sublingual Tablets (generic equivalent to Suboxone®)
Purdue has partnered with MMCAP Infuse, a national cooperative group purchasing organization, to provide this medication to correctional facilities for incarcerated individuals with opioid use disorder. Under the agreement, to increase access to treatment for incarcerated individuals, Purdue will provide approximately 1.25 million tablets for distribution at the cost of one penny ($0.01) per tablet. Read more here. 

Click here for Prescribing Information.

2.  Opioid Overdose Treatment

Nalmefene Vial
Nalmefene HCl injection is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids, and is indicated in the management of known or suspected opioid overdose. Nalmefene HCl injection is FDA-approved and available to purchase through Authorized Distributors at no profit to Purdue. Nalmefene Hydrochloride injection is contraindicated in patients with a known hypersensitivity to the product.  

Click here to learn more, and here for Prescribing Information. 

Nalmefene Auto-injector
In August 2024, FDA approved the Company’s new drug application for Zurnai™ (nalmefene injection) Auto-Injector. Zurnai (zur nye) is a single-dose auto-injector that delivers 1.5 mg of nalmefene hydrochloride per actuation. Zurnai is indicated for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression. Zurnai is intended for immediate administration as emergency therapy in settings where opioids may be present. Zurnai is not a substitute for emergency medical care. Zurnai is contraindicated in patients known to be hypersensitive to nalmefene hydrochloride or to any other ingredients in the product. 

Click here to learn more, and here for Prescribing Information. 

The above efforts supplement the work Purdue has done to assist Harm Reduction Therapeutics (HRT) with the development and FDA approval of RiVive™:

3.  Opioid Overdose Treatment – Over-the-Counter (OTC) Naloxone Nasal Spray
HRT is an independent, non-profit pharmaceutical company that developed and is distributing the over-the-counter naloxone nasal spray, RiVive™ (Naloxone HCl Nasal Spray 3 mg) for the emergency treatment of opioid overdose. HRT’s mission is to save lives that would have otherwise been lost to opioid overdose by making OTC low-price naloxone available to everyone in the United States. Since 2018, Purdue has supported HRT’s mission by contributing tens of millions of dollars, extensive technical expertise, and rights to important data to support the development of this important medication. HRT is distributing RiVive at cost or below cost and no company, individual, or entity will profit from the sale of RiVive. Click here to learn more. 

 

×

Privacy Policy Updates

Please read carefully the Purdue Pharma L.P. Privacy Policy (the “Privacy Policy”), which is part of the Purdue Pharma L.P. Terms and Conditions, before you access, download, or otherwise use any of our websites, related other parties’ websites, mobile applications, or any electronic service (collectively, the “Service”). This Privacy Policy describes the information collected through Your use of the Service, how we use it, how we share it, how we protect it, and the choices You can make about Your information.